Hypofractionation in COVID-19 radiotherapy: A mix of evidence based medicine and of opportunities
Hypofractionation in COVID-19 radiotherapy: A mix of evidence based medicine and of opportunities
复制标题
DOI:
10.1016/j.radonc.2020.06.036
复制
发表时间:
2020-09-01
影响因子:
5.7
通讯作者:
Bambace, S.
中科院分区:
文献类型:
--
作者:
Portaluri, M.;Barba, M. C.;Bambace, S.
Since January 2020, the spread of the COVID-19 pandemic in China and, in the next weeks, in Italy and then in the rest of Europe and the world, has had an enormous impact on the organization, safety procedures and prescription behavior of the physicians in radiation oncology. The main concerns expressed in the numerous comments, letters and papers published in the last three months are (a) how to assure the normal supply of the radiotherapy treatments;(b) how to keep constant the number of Healthcare Workers (HCW);(c) how to identify radiotherapy (RT) patients SARS-CoV-2 positive;(d) how to protect HCW from the viral infection;(e) how to protect the patients from the infections;(f) how to reduce the postponing and the delay of RT start. In previous communications, the initial modifications of the clinical activity in a radiotherapy department in Southern Italy–an area with a relative of low incidence of infections–were described soon after the declaration of the pandemic [1] and some criticism were addressed towards the safety recommendations of the national governmental and the scientific institutions, as they were contradictory and arguably inadequate to ensure patients’ and HCWs’ safety [2]. Many papers have been published with the aim to resume the Hypofractionated (HF) schedules which are considered more suitable for avoiding many visits to the hospital centre, for respecting the time between surgery and RT and thus reducing the risk of infection. Last 29 April, a search on Pubmed (www. pubmed. gov) based on the query radiotherapy+ covid-19 gave 53 papers. Among these, we selected those regarding fractionation scenario. In Table 1, the HF schedules proposed in this pandemic period, from different countries, are summarized [3–14]. They are well known schedules, already used with different motivations:(a) short life expectancy or poor general conditions;(b) advanced age and logistic problems in reaching the RT hospital;(c) radiobiological evidence in tumors with higher sensitivity than conventional fraction dose (breast, prostate);(d) the need to reduce inpatient stay for palliative treatments;(e) the increasing demand of> RT, in countries with universal access to health services, produced a relative shortage of machines and an increasing of waiting times.Evidence-based decisions are a cornerstone also in medical sciences, at least at theoretical; its matching in the practices is however, sometimes, difficult to detect. For instance, point e) of the motivations for prescribing HF schedules, in Italy it is difficult to find it in a private setting (also when the private structure supplies radiotherapy on behalf of Health Public Service (HPS)) because reimbursement is on daily session basis. Recently, in the era of dynamic conformational techniques, the use of HF schedule has become more diffuse, also in the private structures, because they obtain in some region–the HPS is regional in Italy–a better reimbursement. During a pandemic, it may happen the occurrence of fault lines in medicine. One of these is the ‘‘willingness on the part of clinicians to abandon the prime dictum of medicine, to do no harm, and rush into treatments that not only may be useless but may well be dangerous.[15] The fact is, most physician are not trained to recognize good science from bad. Nor do they have the time to analyze every study, and too many are willing to ignore the need for reliable evidence when fear sets in”[16]. Are we going to his pitfall?